Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.60 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083909 | 0.90 | NR4A2 (0.62) | NR4A2CREBBPFGFR1HSD17B1ESR1 | |
| SCHEMBL31048762 | 0.84 | NR4A2 (0.72) | NR4A2CREBBPCA12CA1CA2 | |
| SCHEMBL2434449 | 0.84 | NR4A2 (0.72) | NR4A2CREBBPCA12CA1CA2 | |
| SCHEMBL2770758 | 0.79 | HSD17B1 (0.56) | FGFR1HSD17B1ESR1ESR2CA12 | |
| SCHEMBL6588128 | 0.76 | NR4A2 (1.00) | NR4A2CREBBPNPC1 | |
| SCHEMBL498008 | 0.76 | HSD17B1 (0.44) | FGFR1HSD17B1ESR1ESR2CA12 | |
| SCHEMBL2770364 | 0.76 | PDK2 (0.50) | FGFR1HSD17B1ESR1ESR2CA12 | |
| SCHEMBL2775281 | 0.76 | CA12 (0.50) | FGFR1HSD17B1ESR1ESR2CA12 | |
| SCHEMBL31147988 | 0.76 | NR4A2 (0.63) | NR4A2CREBBP | |
| SCHEMBL497991 | 0.75 | NR4A2 (0.51) | NR4A2HSD17B1ESR1ESR2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984360-B1 | Compounds and methods for modulating FX-receptors | LILLY CO ELI (US) | 2014-01-15 | — | — | EP | disclosed |
| CN-101374834-B | Compounds and methods for modulating FXR | ELI LILLY AND CO. (US) | 2011-12-14 | — | — | CN | disclosed |
| CN-101448791-B | Fxr agonists | LILLY CO ELI | 2011-11-16 | — | — | CN | disclosed |
| US-7863302-B2 | Compounds and methods for modulating FX-receptors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| CN-101448791-A | FXR agonists | LILLY CO ELI (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| CN-101374834-A | Compounds and methods for modulating FXR | LILLY CO ELI (US) | 2009-02-25 | — | — | CN | disclosed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | disclosed |
| EP-1984360-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | Eli Lilly & Company (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007092751-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | NR4A2 263/4885CREBBP 824/4885FGFR1 213/4885 |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | NR4A2 1079/4885CREBBP 1790/4885FGFR1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.